Compare DCTH & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | BWAY |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.4M | 547.7M |
| IPO Year | 2015 | 2011 |
| Metric | DCTH | BWAY |
|---|---|---|
| Price | $15.41 | $12.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $24.00 | $19.27 |
| AVG Volume (30 Days) | ★ 281.2K | 77.2K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.61 | $32.42 |
| Revenue Next Year | $24.27 | $23.40 |
| P/E Ratio | $396.00 | ★ $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $11.77 |
| 52 Week High | $17.42 | $26.63 |
| Indicator | DCTH | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 31.45 |
| Support Level | $15.68 | $11.90 |
| Resistance Level | $16.51 | $14.83 |
| Average True Range (ATR) | 0.43 | 0.55 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 48.67 | 0.61 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.